CStone Pharmaceuticals (2616.HK)

HKD 2.39

(-6.64%)

EBITDA Summary of CStone Pharmaceuticals

  • CStone Pharmaceuticals's latest annual EBITDA in 2023 was -297.22 Million CNY , up 39.52% from previous year.
  • CStone Pharmaceuticals's latest quarterly EBITDA in 2024 Q1 was 1.61 Million CNY , up 100.94% from previous quarter.
  • CStone Pharmaceuticals reported an annual EBITDA of -849.66 Million CNY in 2022, up 56.96% from previous year.
  • CStone Pharmaceuticals reported an annual EBITDA of -1.89 Billion CNY in 2021, down -51.59% from previous year.
  • CStone Pharmaceuticals reported a quarterly EBITDA of 1.61 Million CNY for 2024 Q1, up 100.94% from previous quarter.
  • CStone Pharmaceuticals reported a quarterly EBITDA of N/A for 2023 FY, up 39.52% from previous quarter.

Annual EBITDA Chart of CStone Pharmaceuticals (2023 - 2016)

Historical Annual EBITDA of CStone Pharmaceuticals (2023 - 2016)

Year EBITDA EBITDA Growth
2023 -297.22 Million CNY 39.52%
2022 -849.66 Million CNY 56.96%
2021 -1.89 Billion CNY -51.59%
2020 -1.2 Billion CNY 22.03%
2019 -1.73 Billion CNY -68.98%
2018 -1.02 Billion CNY -242.4%
2017 -241.66 Million CNY -8.21%
2016 -262.1 Million CNY 0.0%

Peer EBITDA Comparison of CStone Pharmaceuticals

Name EBITDA EBITDA Difference
Uni-Bio Science Group Limited 91.23 Million HKD 425.783%
CK Life Sciences Int'l., (Holdings) Inc. 486.79 Million HKD 161.057%